Advaxis, Inc. (ADXS) Lowered to Strong Sell at ValuEngine

Advaxis, Inc. (NASDAQ:ADXS) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Tuesday.

Other analysts have also recently issued reports about the stock. BidaskClub cut shares of Advaxis from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $19.00 price target on shares of Advaxis in a report on Wednesday, May 31st. Finally, HC Wainwright set a $23.00 price target on shares of Advaxis and gave the company a “buy” rating in a report on Wednesday, June 14th. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. Advaxis presently has an average rating of “Hold” and an average price target of $22.00.

Shares of Advaxis (NASDAQ ADXS) opened at 6.23 on Tuesday. Advaxis has a 12-month low of $5.70 and a 12-month high of $16.30. The firm has a 50-day moving average of $6.60 and a 200-day moving average of $7.96. The firm’s market cap is $252.08 million.

COPYRIGHT VIOLATION NOTICE: “Advaxis, Inc. (ADXS) Lowered to Strong Sell at ValuEngine” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://sportsperspectives.com/2017/08/10/advaxis-inc-adxs-lowered-to-strong-sell-at-valuengine.html.

A number of hedge funds have recently bought and sold shares of ADXS. Wells Fargo & Company MN boosted its stake in Advaxis by 0.8% in the first quarter. Wells Fargo & Company MN now owns 43,669 shares of the biotechnology company’s stock valued at $356,000 after buying an additional 360 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Advaxis by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 129,321 shares of the biotechnology company’s stock valued at $840,000 after buying an additional 817 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Advaxis by 4.8% in the first quarter. PNC Financial Services Group Inc. now owns 22,000 shares of the biotechnology company’s stock valued at $180,000 after buying an additional 1,000 shares in the last quarter. SG Americas Securities LLC boosted its stake in Advaxis by 2.9% in the first quarter. SG Americas Securities LLC now owns 49,333 shares of the biotechnology company’s stock valued at $403,000 after buying an additional 1,398 shares in the last quarter. Finally, American International Group Inc. boosted its stake in Advaxis by 7.6% in the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 1,459 shares in the last quarter. 54.95% of the stock is currently owned by hedge funds and other institutional investors.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply